NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW – Get Free Report) saw a large growth in short interest during the month of October. As of October 30th, there was short interest totaling 5,262 shares, a growth of 473.2% from the October 15th total of 918 shares. Based on an average daily volume of 2,157 shares, the days-to-cover ratio is currently 2.4 days.
NeuroSense Therapeutics Stock Up 35.7%
NASDAQ:NRSNW traded up $0.00 on Wednesday, reaching $0.01. 23,085 shares of the stock traded hands, compared to its average volume of 3,754. The company’s fifty day simple moving average is $0.03 and its 200 day simple moving average is $0.13. NeuroSense Therapeutics has a 12 month low of $0.00 and a 12 month high of $0.47.
NeuroSense Therapeutics Company Profile
NeuroSense Therapeutics Ltd. is an Israel-based clinical-stage biotechnology company developing treatments for neurodegenerative diseases. Its research focuses on biological processes associated with nerve-cell damage and disease progression. The company’s lead investigational product, PrimeC, is an oral formulation combining ciprofloxacin and celecoxib. NeuroSense is developing PrimeC primarily for amyotrophic lateral sclerosis (ALS); it is investigational and has not been approved as a treatment.
Featured Stories
- Five stocks we like better than NeuroSense Therapeutics
- Alphabet Escalates AI Chip Rivalry With NVIDIA
- Amazon’s Rally Is Outpacing Big Tech, But Can AWS Justify the AI Spending?
- 3 Stocks Wall Street Likes More Than the Market Does
- Anthropic’s Trillion-Dollar IPO Could Give Cloud Giants a Double Win
Receive News & Ratings for NeuroSense Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroSense Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
